Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07691606 · ClinicalTrials.gov registry record · Phase 1
A Study of ARC-02 in B-cell NHL
A Phase 1 study, sponsored by Taiho Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT07691606: Recruiting Phase 1 study, sponsored by Taiho Oncology.
NCT07691606 is a Phase 1 study that is actively recruiting participants, run by Taiho Oncology. The registered enrollment target is 140 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07691606, a Phase 1 study, is actively recruiting participants, sponsored by Taiho Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
Interventions
- DRUG Rituximab
- DRUG ARC-02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-06-04 |
| Est. Completion | 2030-12 |
| Phase | Phase 1 |
What NCT07691606 shows while recruiting
NCT07691606 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT07691606 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07691606 about?
NCT07691606 is a clinical study titled "A Study of ARC-02 in B-cell NHL". This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
What is the current status of trial NCT07691606?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2026-06-04. Estimated completion is 2030-12.
What interventions are being tested in trial NCT07691606?
The interventions under investigation include: Rituximab (DRUG), ARC-02 (DRUG).
Who is sponsoring clinical trial NCT07691606?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07691606's enrollment target sits among peer trials
140 402nd of 2000 higher than 1,583 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI